Monopar Therapeutics MNPR Stock
Monopar Therapeutics Price Chart
Monopar Therapeutics MNPR Financial and Trading Overview
| Monopar Therapeutics stock price | 40.81 USD |
| Previous Close | 0.85 USD |
| Open | 0.83 USD |
| Bid | 0 USD x 900 |
| Ask | 0 USD x 800 |
| Day's Range | 0.81 - 0.86 USD |
| 52 Week Range | 0.81 - 4.88 USD |
| Volume | 117.75K USD |
| Avg. Volume | 288.24K USD |
| Market Cap | 11.18M USD |
| Beta (5Y Monthly) | 0.994548 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.11 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.1 USD |
MNPR Valuation Measures
| Enterprise Value | -499627 USD |
| Trailing P/E | N/A |
| Forward P/E | -1.8784446 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 1.2504438 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | N/A |
Trading Information
Monopar Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.994548 |
| 52-Week Change | -63.26% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 4.88 USD |
| 52 Week Low | 0.81 USD |
| 50-Day Moving Average | 1.04 USD |
| 200-Day Moving Average | 2.15 USD |
MNPR Share Statistics
| Avg. Volume (3 month) | 288.24K USD |
| Avg. Daily Volume (10-Days) | 158.44K USD |
| Shares Outstanding | 13.22M |
| Float | 4.23M |
| Short Ratio | 0.23 |
| % Held by Insiders | 62.59% |
| % Held by Institutions | 1.42% |
| Shares Short | 84.33K |
| Short % of Float | 1.77% |
| Short % of Shares Outstanding | 0.64% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -44.33% |
| Return on Equity (ttm) | -80.99% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | N/A |
| Net Income Avi to Common (ttm) | -10493472 USD |
| Diluted EPS (ttm) | -0.78 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 11.68M USD |
| Total Cash Per Share (mrq) | 0.88 USD |
| Total Debt (mrq) | 0 USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 4.08 |
| Book Value Per Share (mrq) | 0.676 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -7032172 USD |
| Levered Free Cash Flow (ttm) | -3109842 USD |
Profile of Monopar Therapeutics
| Country | United States |
| State | IL |
| City | Wilmette |
| Address | 1000 Skokie Boulevard |
| ZIP | 60091 |
| Phone | 847 388 0349 |
| Website | https://www.monopartx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 11 |
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Q&A For Monopar Therapeutics Stock
What is a current MNPR stock price?
Monopar Therapeutics MNPR stock price today per share is 40.81 USD.
How to purchase Monopar Therapeutics stock?
You can buy MNPR shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Monopar Therapeutics?
The stock symbol or ticker of Monopar Therapeutics is MNPR.
Which industry does the Monopar Therapeutics company belong to?
The Monopar Therapeutics industry is Biotechnology.
How many shares does Monopar Therapeutics have in circulation?
The max supply of Monopar Therapeutics shares is 6.38M.
What is Monopar Therapeutics Price to Earnings Ratio (PE Ratio)?
Monopar Therapeutics PE Ratio is now.
What was Monopar Therapeutics earnings per share over the trailing 12 months (TTM)?
Monopar Therapeutics EPS is -4.11 USD over the trailing 12 months.
Which sector does the Monopar Therapeutics company belong to?
The Monopar Therapeutics sector is Healthcare.
Monopar Therapeutics MNPR included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17366.13 USD — |
-0.1
|
9.56B USD — | 17128.71 USD — | 17467.35 USD — | — - | 9.56B USD — |
| NASDAQ Capital Market Composite RCMP | 102.11 USD — |
-0.04
|
— — | 100.72 USD — | 103.65 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 931.02 USD — |
+0.81
|
— — | 921.75 USD — | 934.48 USD — | — - | — — |
- {{ link.label }} {{link}}